BCL2 and diffuse large B-cell lymphoma: We observed poorer ECOG performance status, higher IPI scores, and a higher percentage of MYC/BCL2 double expression subtype in the old subgroup but not other clinical and pathological features, such as advanced disease stage, elevated LDH level, and multiple extranodal involvements, which were reported to be more frequently presented in the old DLBCL patients in a previous study [4].